The global NGS sample preparation market is projected to generate a revenue of $5,501.2 million in 2030, advancing at a CAGR of 14.7% during 2020–2021. This can be ascribed to the rising prevalence of infectious diseases, technological advancement in NGS sample preparation methods, and surging incidence of genetic disorders. Furthermore, the increasing funding and research grants for R&D in the field of genomics fuel the growth of the market.
The automated workstation category is expected to witness the fastest growth in the market, with a CAGR of around 15.0%, during the forecast period. The demand for automated workstations has increased in recent years, as these provide numerous advantages compared to conventional procedures. Also, the workstation has the ability to prepare up to 10 times more samples than the manual workflow, in the same period.
On the other hand, the consumables category accounted for the largest revenue in 2021, and it is expected to maintain the same trend during the forecast period as well. This is ascribed to the huge demand for testing instruments in the research field for DNA, RNA, and whole-genome sequencing.
The infectious diseases category is projected to grow at the highest CAGR during the forecast period, based on therapeutic area. This is because the advanced next-generation sequencing technologies have opened up the possibility of developing a comprehensive strategy for identifying infectious pathogens. Moreover, NGS is used to screen and diagnose novel viruses and diseases that escape from standard testing.
Academic and research institutions are expected to contribute the largest revenue to the market, based on end user, in the coming years. This can be attributed to the rapid advancement in R&D dedicated to the development of new technologies for the improvement and upgradation of NGS products and services.
Geographically, North America leads the NGS sample preparation market, owing to the high adoption rate of sequencing technologies and NGS sample preparation sequencing solutions. Whereas, the APAC market is expected to witness the fastest growth during 2021–2030. This can be ascribed to the increase in the number of NGS-based research and clinical applications and the favorable initiatives taken by the government and private bodies for the development and adoption of NGS technologies.
To secure a good position in the market, key players have been engaged in partnerships and mergers and acquisitions. For instance, in March 2021, Integrated DNA Technologies Inc. acquired Swift Biosciences Inc. to expand its library preparation and enrichment products portfolio.
Similarly, in June 2020, F. Hoffmann-La Roche Ltd. and Illumina Inc. announced their non-exclusive partnership to expand the use of distributable next-generation sequencing-based oncology testing.
Some of the key players in the NGS sample preparation market are Agilent Technologies Inc., Becton, Dickinson and Company, Beckman Coulter Inc., F. Hoffmann-La Roche Ltd., Illumina Inc., New England Biolabs Inc., Integrated DNA Technologies Inc., Oxford Nanopore Technologies plc, and Pacific Biosciences of California Inc.